NCT06503796View on ClinicalTrials.gov

Antiviral Therapy in Infants With HBV Infection

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 31, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2026

Conditions
HBV
Interventions
DRUG

Lamivudine

4mg/kg/d, oral

DRUG

Interferon

Use only in children who remain positive for HBV-DNA and/or HBsAg after 1 year of age. Regular interferon (3 million U/m2 body surface area, intramuscular or subcutaneous, every other day, adjusted during treatment according to the child's specific tolerance) for 52 weeks.

Trial Locations (1)

Unknown

the Fifth Medical Center of PLA, Beijing

All Listed Sponsors
lead

Beijing 302 Hospital

OTHER

NCT06503796 - Antiviral Therapy in Infants With HBV Infection | Biotech Hunter | Biotech Hunter